CD22 and acute lymphoblastic leukemia: A limitation of our clinical study is the absence of comparator groups, specifically those receiving CD19 CAR-T cell infusion, CD22 CAR-T cell infusion, or a combination of CD19/CD22 CAR-T cell infusions, which would elucidate therapeutic efficacies in r/r B-ALL patients.